Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376955 | 0.90 | MAPK14 (0.56) | MAPK14GSK3BBACE1MAOB | |
| SCHEMBL4381727 | 0.87 | MAPK14 (0.65) | MAPK14GSK3BBACE1MAOB | |
| SCHEMBL4379278 | 0.86 | MAPK14 (0.67) | MAPK14MAOB | |
| SCHEMBL4374553 | 0.86 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL4381266 | 0.85 | MAPK14 (0.65) | MAPK14MAOB | |
| SCHEMBL6471335 | 0.85 | MAPK14 (0.47) | MAPK14GSK3BBACE1MAOB | |
| SCHEMBL4376213 | 0.85 | MAPK14 (0.45) | MAPK14GSK3BBACE1MAOB | |
| SCHEMBL4381768 | 0.82 | MAPK14 (0.70) | MAPK14MAOB | |
| SCHEMBL13610118 | 0.81 | GSK3B (0.47) | MAPK14GSK3BBACE1MAOB | |
| SCHEMBL4377643 | 0.81 | MAPK14 (0.78) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885GSK3B 1243/4885BACE1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.